Figure1 | THE EFFICACY, SAFETY, AND NET CLINICAL BENEFIT OF CANGRELOR IN WOMEN UNDERGOING ELECTIVE OR URGENT PCI: INSIGHTS FROM THE CHAMPION-PHOENIX TRIAL | JACC: Journal of the American College of Cardiology
Efficacy outcomes at 30 days in CHAMPION-PHOENIX trial. | Download Table
Figure S1: CHAMPION PHOENIX Study Design | Download Scientific Diagram
CHAMPION PHOENIX trial
Consistent Reduction in MI with Cangrelor Deepak L - ppt download
Investigator-Reported Bleeding Versus Post Hoc Adjudication of Bleeding: Lessons From the CHAMPION PHOENIX Trial | Journal of the American College of Cardiology
Off Hours” Versus “On Hours” Presentation in ST-Segment Elevation Myocardial Infarction: Findings from CHAMPION PHOENIX | tctmd.com
Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events | NEJM
Incidence and Impact of Stent Thrombosis During Percutaneous Coronary Intervention: Comparison of Cangrelor and Clopidogrel from the CHAMPION PHOENIX Trial | tctmd.com
The Effect of Cangrelor and Access Site on Ischemic and Bleeding Events – Insights from CHAMPION PHOENIX J. Antonio Gutierrez, MD, MHS, Robert A. Harrington, - ppt download
60104-8.fp.png "THE EFFICACY, SAFETY, AND NET CLINICAL BENEFIT OF CANGRELOR IN WOMEN UNDERGOING ELECTIVE OR URGENT PCI: INSIGHTS FROM THE CHAMPION-PHOENIX TRIAL | Journal of the American College of Cardiology")
THE EFFICACY, SAFETY, AND NET CLINICAL BENEFIT OF CANGRELOR IN WOMEN UNDERGOING ELECTIVE OR URGENT PCI: INSIGHTS FROM THE CHAMPION-PHOENIX TRIAL | Journal of the American College of Cardiology
Impact of Intraprocedural Stent Thrombosis During Percutaneous Coronary Intervention
Figure S1: CHAMPION PHOENIX Study Design | Download Scientific Diagram
Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events | NEJM
CHAMPION PHOENIX: Effect of Cangrelor and Access Site on Ischemic and Bleeding Events | tctmd.com
Pro Position: The Data - Phoenix and Meta-Analysis of the Champion Clinical Trial Program! | tctmd.com
TCT 79: Efficacy of Cangrelor in Lesions With High-Risk and Low-Risk Angiographic Characteristics – The CHAMPION PHOENIX Trial | tctmd.com
Table 3 from Making Sense of Statistics in Clinical Trial Reports: Part 1 of a 4-Part Series on Statistics for Clinical Trials. | Semantic Scholar
BCRI - Clinical Trials
Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention | JACC: Cardiovascular Interventions
Impact of Cerebrovascular Events Older Than One Year on Ischemic and Bleeding Outcomes With Cangrelor in Percutaneous Coronary Intervention | Circulation: Cardiovascular Interventions
Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events | NEJM
PPT - CHAMPION PHOENIX PowerPoint Presentation, free download - ID:2257235
30570-9.fp.png "THE EFFICACY AND SAFETY OF CANGRELOR FOR PATIENTS UNDERGOING SINGLE VESSEL VERSUS MULTI VESSEL PERCUTANEOUS CORONARY INTERVENTION: INSIGHTS FROM THE CHAMPION PHOENIX TRIAL | Journal of the American College of Cardiology")
THE EFFICACY AND SAFETY OF CANGRELOR FOR PATIENTS UNDERGOING SINGLE VESSEL VERSUS MULTI VESSEL PERCUTANEOUS CORONARY INTERVENTION: INSIGHTS FROM THE CHAMPION PHOENIX TRIAL | Journal of the American College of Cardiology
Table 5 from Intravenous antiplatelet therapies (glycoprotein IIb/IIIa receptor inhibitors and cangrelor) in percutaneous coronary intervention: from pharmacology to indications for clinical use | Semantic Scholar
CHAMPION-PHOENIX (IV Cangrelor vs Oral Clopidogrel for the Management of Periprocedural PCI Complications)
